| 37.87 -1.12 (-2.87%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 50.1  |
1-year : | 53.87 |
| Resists | First : | 42.9 |
Second : | 46.13 |
| Pivot price | 40.84 |
|||
| Supports | First : | 37.68 |
Second : | 31.34 |
| MAs | MA(5) : | 39.3 |
MA(20) : | 41.64 |
| MA(100) : | 40.37  |
MA(250) : | 37.48 |
|
| MACD | MACD : | -1.5 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 3.9 |
D(3) : | 7.6 |
| RSI | RSI(14): 27.1 |
|||
| 52-week | High : | 49.31 | Low : | 28.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VCEL ] has closed below the lower bollinger band by 1.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 6.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.22 - 39.5 | 39.5 - 39.71 |
| Low: | 37.81 - 38.18 | 38.18 - 38.47 |
| Close: | 38.47 - 38.98 | 38.98 - 39.37 |
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Tue, 08 Sep 2026
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026 - marketscreener.com
Thu, 03 Sep 2026
Liquidity Mapping Around (VCEL) Price Events - Stock Traders Daily
Tue, 04 Aug 2026
Vericel Corporation (VCEL) Stock Analysis: A 31.53% Upside In The Biotech Sector - DirectorsTalk Interviews
Thu, 30 Jul 2026
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates - finance.yahoo.com
Tue, 28 Jul 2026
Vericel Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Thu, 16 Jul 2026
Vericel schedules July 30 webcast for second-quarter update - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 111.1 (%) |
| Shares Short | 4,720 (K) |
| Shares Short P.Month | 4,600 (K) |
| EPS | 0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.23 |
| Profit Margin | 7.9 % |
| Operating Margin | 0.5 % |
| Return on Assets (ttm) | 2.4 % |
| Return on Equity (ttm) | 7.1 % |
| Qtrly Rev. Growth | 22.5 % |
| Gross Profit (p.s.) | 4.45 |
| Sales Per Share | 5.98 |
| EBITDA (p.s.) | 0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 70 (M) |
| Levered Free Cash Flow | 56 (M) |
| PE Ratio | 78.69 |
| PEG Ratio | 0 |
| Price to Book value | 5.22 |
| Price to Sales | 6.31 |
| Price to Cash Flow | 27.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|